CytoCalx Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$12.5K
- Investors
-
1
CytoCalx General Information
Description
Developer of a biomarker assay designed to estimate the risk and severity of chronic kidney and cardiovascular diseases. The company offers a test that accurately measures active tissue calcification levels in blood samples, enabling healthcare professionals to better assess patient conditions and tailor interventions.
Contact Information
Corporate Office
- Cambridge
- England, United Kingdom
Corporate Office
- Cambridge
- England, United Kingdom
CytoCalx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | 16-May-2023 | $12.5K | Completed | Startup |
CytoCalx Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Accelerate@Babraham | Accelerator/Incubator |
CytoCalx FAQs
-
When was CytoCalx founded?
CytoCalx was founded in 2023.
-
Where is CytoCalx headquartered?
CytoCalx is headquartered in Cambridge, United Kingdom.
-
What industry is CytoCalx in?
CytoCalx’s primary industry is Other Healthcare Services.
-
Is CytoCalx a private or public company?
CytoCalx is a Private company.
-
What is CytoCalx’s current revenue?
The current revenue for CytoCalx is .
-
How much funding has CytoCalx raised over time?
CytoCalx has raised $12.5K.
-
Who are CytoCalx’s investors?
Accelerate@Babraham has invested in CytoCalx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process